KR20010042765A - Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 그리고 ｎａｄｈ및/또는 ｎａｄｐｈ가 포함되는 조성물 - Google Patents

Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 그리고 ｎａｄｈ및/또는 ｎａｄｐｈ가 포함되는 조성물 Download PDF

Info

Publication number
KR20010042765A
KR20010042765A KR1020007011499A KR20007011499A KR20010042765A KR 20010042765 A KR20010042765 A KR 20010042765A KR 1020007011499 A KR1020007011499 A KR 1020007011499A KR 20007011499 A KR20007011499 A KR 20007011499A KR 20010042765 A KR20010042765 A KR 20010042765A
Authority
KR
South Korea
Prior art keywords
carnitine
composition
nadh
alkanoyl
acid
Prior art date
Application number
KR1020007011499A
Other languages
English (en)
Korean (ko)
Inventor
카바쟈클라우디오
Original Assignee
피에트로 폴라
시그마-타우 헬스사이언스 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에트로 폴라, 시그마-타우 헬스사이언스 에스.피.에이 filed Critical 피에트로 폴라
Publication of KR20010042765A publication Critical patent/KR20010042765A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020007011499A 1998-04-17 1999-04-14 Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 그리고 ｎａｄｈ및/또는 ｎａｄｐｈ가 포함되는 조성물 KR20010042765A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM98A000238 1998-04-17
IT98RM000238A IT1299161B1 (it) 1998-04-17 1998-04-17 Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
PCT/IT1999/000088 WO1999053921A1 (fr) 1998-04-17 1999-04-14 Composition comprenant de la l-carnitine ou un alcanoyl l-carnitine et nadh et/ou nadph

Publications (1)

Publication Number Publication Date
KR20010042765A true KR20010042765A (ko) 2001-05-25

Family

ID=11405812

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007011499A KR20010042765A (ko) 1998-04-17 1999-04-14 Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 그리고 ｎａｄｈ및/또는 ｎａｄｐｈ가 포함되는 조성물

Country Status (17)

Country Link
EP (1) EP1071424A1 (fr)
JP (1) JP2002512191A (fr)
KR (1) KR20010042765A (fr)
CN (1) CN1299283A (fr)
AU (1) AU750645B2 (fr)
BR (1) BR9909712A (fr)
CA (1) CA2328331A1 (fr)
EE (1) EE200000601A (fr)
HU (1) HUP0101914A3 (fr)
IL (1) IL139014A0 (fr)
IS (1) IS5663A (fr)
IT (1) IT1299161B1 (fr)
NO (1) NO20005128L (fr)
PL (1) PL343482A1 (fr)
SK (1) SK15442000A3 (fr)
TR (1) TR200002894T2 (fr)
WO (1) WO1999053921A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252309B2 (en) 2000-04-04 2012-08-28 Sigma-Tau Industrie Farmaceutiche Riunite Spa Dietary supplement energy-providing to skeletal muscles
DE10326822A1 (de) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
MX2009012042A (es) * 2007-05-11 2009-12-01 Sigma Tau Ind Farmaceuti Gel util para el suministro de ingredientes activos cosmeticos.
WO2011022786A1 (fr) * 2009-08-31 2011-03-03 Pharmaqest Pty Ltd Procédés de diagnostic et de traitement du syndrome de fatigue chronique
CN104306390A (zh) * 2014-10-23 2015-01-28 苏州人本药业有限公司 还原型辅酶ⅱ的用途
CN104840479A (zh) * 2015-02-17 2015-08-19 苏州人本药业有限公司 Nadph在制备治疗心脏疾病药物中的应用
ES2786774B2 (es) * 2017-12-22 2022-03-04 Bontac Bio Eng Shenzhen Co Ltd Composición para compuesto de coenzima NADH, preparación y aplicación del mismo.
PL3755160T3 (pl) 2018-04-20 2022-02-14 Pacotrade Ag Urządzenie do rozdrabniania głęboko mrożonych środków spożywczych przygotowanych w formie bloku
CN109170907A (zh) * 2018-08-30 2019-01-11 泓博元生命科技（深圳）有限公司 一种含有nmn的组合物、应用及运动饮料的制备方法
CN109105702A (zh) * 2018-08-30 2019-01-01 泓博元生命科技（深圳）有限公司 一种含有nadh的组合物、应用及能量补充剂的制备方法
CA3115743A1 (fr) * 2018-10-10 2020-04-16 So Ngor Sally LEUNG Composition de produit de sante permettant de compenser un deficit, son procede de preparation et son application

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054698A (fr) * 1964-12-04
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
JPH09110708A (ja) * 1995-08-11 1997-04-28 Taisho Pharmaceut Co Ltd 滋養強壮用生薬配合製剤
JPH0959161A (ja) * 1995-08-23 1997-03-04 Taisho Pharmaceut Co Ltd 疲労改善用組成物
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
JPH10175856A (ja) * 1996-10-14 1998-06-30 Taisho Pharmaceut Co Ltd 疲労改善剤

Also Published As

Publication number Publication date
EE200000601A (et) 2002-04-15
IS5663A (is) 2000-10-13
CA2328331A1 (fr) 1999-10-28
TR200002894T2 (tr) 2001-01-22
WO1999053921A1 (fr) 1999-10-28
NO20005128L (no) 2000-12-18
SK15442000A3 (sk) 2001-06-11
IT1299161B1 (it) 2000-02-29
HUP0101914A3 (en) 2002-12-28
BR9909712A (pt) 2000-12-26
NO20005128D0 (no) 2000-10-12
JP2002512191A (ja) 2002-04-23
IL139014A0 (en) 2001-11-25
HUP0101914A2 (hu) 2002-03-28
ITRM980238A1 (it) 1999-10-17
ITRM980238A0 (it) 1998-04-17
PL343482A1 (en) 2001-08-27
AU750645B2 (en) 2002-07-25
CN1299283A (zh) 2001-06-13
AU3442899A (en) 1999-11-08
EP1071424A1 (fr) 2001-01-31

Similar Documents

Publication Publication Date Title
Abraham et al. Management of fibromyalgia: rationale for the use of magnesium and malic acid
CA2784836C (fr) Procede ameliore permettant d'administrer du .beta.-hydroxy-.beta.-methylbutyrate (hmb)
KR20010005865A (ko) 격렬한 운동에 대한 골격근 적응을 촉진하고 허약 체질자의 피로 회복에 유용한 영양 보조제
KR20010042765A (ko) Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 그리고 ｎａｄｈ및/또는 ｎａｄｐｈ가 포함되는 조성물
WO2009139156A1 (fr) Agent thérapeutique pour la stérilité masculine
LV10386B (en) Pharmaceutical composition and process for the preparation thereof
US4296119A (en) Process and composition for reducing blood pressure in animals
KR100817348B1 (ko) 심부전 치료에 적합한 아미노산 기초 조성물
CZ20014077A3 (cs) Doplňková výľiva dodávající energii kosternímu svalstvu a chránící kardiovaskulární systém
Sved et al. Dietary protein intake influences the antihypertensive potency of methyldopa in spontaneously hypertensive rats.
Maher Effects of nutrients on brain function
WO1993017691A2 (fr) Compositions pharmaceutiques contenant du monosialoganglioside gm1 ou un derive de celui-ci, convenant ou traitement de la maladie de parkinson
MXPA00009983A (en) Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
US20060105965A1 (en) Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations
JP2008508312A (ja) 筋肉エネルギー産生増強目的のためのメチルピルベートの用途
Stacy Pharmacotherapy for advanced Parkinson's disease
CA2959109A1 (fr) Procede d'amelioration de la production d'energie et du metabolisme dans des cellules
US11376271B1 (en) Methods of ameliorating the effects of alcoholic liver damage
CZ20003831A3 (cs) Přípravek obsahující L-karnitin nebo alkanoyl Lkarnitinu a NADH a/nebo NADPH
RU2720134C1 (ru) Фармацевтическая композиция для парентерального капельного введения
RU2721606C1 (ru) Фармацевтическая композиция для парентерального капельного введения
Reichmann et al. Dopamine and Glutamate in Parkinson’s Disease: Biochemistry, Clinical Aspects, and Treatment
Youdim et al. 4 Monoamine Oxidase Type B Inhibitors in the Treatment of Parkinson's Disease
Fischer Parkinson’s disease and its existing therapy
GB2178661A (en) Pharmaceutical compositions containing ubiquinone coenzymes

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid